U.S. taxpayers spent billions developing Ozempic-type diabetes and weight-loss drugs — now those drugs’ markups could ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare ...

The Department of Social Services remains committed to exploring policy solutions that maximize health outcomes while maintaining fiscal sustainability ...

Republicans trying to find billions of Medicaid dollars to pay for tax cuts now say that any reduction in Medicaid spending ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Health insurance companies are lobbying against proposals that would expand prescription access to weight-loss medications.

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...